leadf
logo-loader
viewCytoDyn Inc.

CytoDyn files to uplist to tech-heavy Nasdaq stock exchange

The company, which is developing leronlimab to treat multiple diseases including coronavirus (COVID-19), said its application package should satisfy initial listing requirements

Nasdaq
CytoDyn has started enrolling a Phase 2b/3 clinical trial for 390 severe and critically ill COVID-19 patients

CytoDyn Inc (OTCQB:CYDY), which is developing leronlimab (PRO 140) to battle multiple diseases including coronavirus (COVID-19), has filed to uplist its stock to the tech-laded Nasdaq stock exchange.

In a statement, the Vancouver, Washington-based company said it believes its comprehensive application package satisfies the initial listing requirements for The Nasdaq Capital Market.

“While we realize the regulatory review of our application to uplist to Nasdaq will take several weeks, we believe the company is well-positioned for success,” noted CEO Nader Pourhassan. 

READ: CytoDyn says leronlimab prevents transmission of simian HIV in pre-clinical study on macaques

“As we advance the evaluation of our drug, leronlimab, including the upcoming results of the COVID-19 trials, we believe a listing on Nasdaq will enhance shareholder value by providing our shareholders with improved liquidity and by giving us greater access to the capital markets, which will allow us to achieve our objective of bringing leronlimab to market,” Pourhassan added.

As a possible COVID-19 treatment, the US Food and Drug Administration has granted a so-called rolling review for leronlimab as part of CytoDyn's application submission. The company has been granted more than 60 emergency Investigational New Drug authorizations by the FDA and plans to provide clinical updates for this patient population in the coming weeks.

In July, CytoDyn started enrolling a Phase 2b/3 clinical trial for 390 severe and critically ill COVID-19 patients, which were randomized in a 2:1 ratio, in an active drug to placebo-controlled trial.

CytoDyn also said it has met its 75-patient enrollment target in its Phase 2 clinical trial for COVID-19, a randomized clinical study for mild-to-moderate COVID-19 patients in the US.

Leronlimab has also been granted Fast Track designation by the FDA for the treatment of HIV in combination with highly active antiretroviral therapy (HAART,) and for metastatic triple-negative breast cancer, a rare variety which doesn’t respond to some treatments. 

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: CytoDyn Inc.

Price: 2.28 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $1.3 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

CytoDyn provide update on their path to approval for treatment of COVID-19

CytoDyn (OTCQB: CYDY) CEO Nader Pourhassan joined Steve Darling from Proactive to provide an update on how and when they expect to have approval for Leronlimab for Covid treatment.  Pourhassan also told Proactive about what the recent decision by the FDA to approve Remdesivir as a...

3 days, 12 hours ago

2 min read